YntraDose (yttrium-90 microspheres) / BetaGlue Therapeutics - LARVOL DELTA

In vivo preclinical evaluation of YntraDose™ in pig's lung: A pilot study of a 90Y-microsphere device implantation. (PubMed, Nucl Med Biol) - "This first in vivo preclinical investigation demonstrates that YntraDose™ can be successfully injected and polymerized in lung tissue, even at high radioactivity levels. Despite the intense inflammatory reaction observed, the results support further preclinical studies with optimized, clinically relevant 90Y activities to evaluate the potential of YntraDose™ for localized lung tumor ablation."

Journal • Preclinical • Lung Cancer • Oncology • Solid Tumor • CXCL8 • IL1B • IL6

Development of a Synthetic Liver Phantom: Experimental Characterization of Tissue Mechanical Properties. (PubMed, Ann Biomed Eng) - "The proposed phantom provides a controlled experimental platform for investigating the mechanical and transport behavior of injectable agents in liver-mimicking tissue. While not intended for clinical or regulatory equivalence, this research-grade model bridges the gap between simplified in vitro systems and in vivo studies, supporting preclinical research and device development."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

One Month Preclinical Safety and Efficacy Evaluation of a Yttrium-90 Resin Microsphere Glue Formulation in the Oncopig® Pancreatic Cancer Model (SIO 2026) - "This work confirms the ability of the Oncopig pancreatic cancer model to provide easily identifiable tumor targets for laparoscopic injection of radiotherapies that are suitable for chronic PET-CT follow up. The results of this study confirm safety and feasibility of intratumor injection of YntraDose in the Oncopig pancreatic cancer model, helping advance translation of this novel therapeutic approach into clinical practice."

Preclinical • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC (clinicaltrials.gov) - P=N/A | N=10 | Recruiting | Sponsor: BetaGlue Therapeutics SpA | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) (The Manila Times) - "The clinical study is expected to begin enrolling patients in early 2026, with preliminary results expected by the end of the year. This early feasibility clinical investigation aims to assess the safety, usability and feasibility of YntraDose administration in patients with unresectable LA-PDAC, a disease with limited effective treatment options and a significant unmet medical need."

New trial • Pancreatic Ductal Adenocarcinoma